Infectious Disease Clinical Trials

Statistical methods in infectious disease trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All infectious disease trials

903 results

• GAMINIIIndependent statistical analysis of Gut and Azithromycin Mechanisms in Infants and Children II: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04315272).Phase 4Results postedn = 449NCT04315272
• Gardasil Vaccination in Post Stem Cell Transplant Patients: Complete Statistical AnalysisIndependent statistical analysis of Gardasil Vaccination in Post Stem Cell Transplant Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01092195).Phase 1Results postedn = 64NCT01092195
• GARGLESIndependent statistical analysis of Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 20NCT04410159
• GEMINI Study – A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection: Complete Statistical AnalysisIndependent statistical analysis of GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 337NCT00105079
• Gene Signatures of Influenza Vaccine Responses in Older Adults: Complete Statistical AnalysisIndependent statistical analysis of Gene Signatures of Influenza Vaccine Responses in Older Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03603509).Phase 4Results postedn = 241NCT03603509
• Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury: Complete Statistical AnalysisIndependent statistical analysis of Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2/3Results postedn = 23NCT03503513
• GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19): Complete Statistical AnalysisIndependent statistical analysis of GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 132NCT04590547
• GLS-5700 in Dengue Virus-Naïve Adults: Complete Statistical AnalysisIndependent statistical analysis of GLS-5700 in Dengue Virus-Naïve Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02809443).Phase 1Results postedn = 40NCT02809443
• GO2 PEEPIndependent statistical analysis of Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 2NCT04331366
• Gown and Glove Use to Prevent the Spread of Infection in VA Community Living Centers: Complete Statistical AnalysisIndependent statistical analysis of Gown and Glove Use to Prevent the Spread of Infection in VA Community Living Centers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 203NCT01350479
• GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.: Complete Statistical AnalysisIndependent statistical analysis of GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV)…Phase 3Results postedn = 429NCT00381303
• Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065): Complete Statistical AnalysisIndependent statistical analysis of Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065): primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 159NCT02252016
• GRC00097Independent statistical analysis of Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively: primary endpoint results, effect estimate with…Phase 4Results postedn = 90NCT04109222
• GREATIndependent statistical analysis of Get Ready And Empowered About Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02165735).Phase NAResults postedn = 360NCT02165735
• Group-Based Intervention to Improve Mental Health and Adherence Among Youth Living With HIV in Low Resource Settings: Complete Statistical AnalysisIndependent statistical analysis of Group-Based Intervention to Improve Mental Health and Adherence Among Youth Living With HIV in Low Resource Settings: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase NAResults postedn = 484NCT04024488
• Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance: Complete Statistical AnalysisIndependent statistical analysis of Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 77NCT00130286
• GS-US-292-0104Independent statistical analysis of GS-US-292-0104 (NCT01780506), a randomized phase 3 trial comparing E/C/F/TAF with E/C/F/TDF in antiretroviral treatment-naive adults with HIV-1 infection, including its non-inferiority analysis, risk difference, confidence interval, and Cochran-Mantel-Haenszel…Phase 3Results postedn = 872NCT01780506
• GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease: Complete Statistical AnalysisIndependent statistical analysis of GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00950807).Phase 2Results postedn = 176NCT00950807
• HAI115879Independent statistical analysis of Dose Ranging of GSK2336805 in Combination Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01648140).Phase 2Results postedn = 286NCT01648140
• HANDmacIndependent statistical analysis of A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 19NCT01449006
• HAPIIndependent statistical analysis of HIV And Parasitic Infection (HAPI) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05323396).Phase NAResults postedn = 120NCT05323396
• HCVIndependent statistical analysis of An Integrated Care Model for Improving Hepatitis C Virus Patient Outcomes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 364NCT00722423
• HEAL-COVIDIndependent statistical analysis of HEAL-COVID (NCT04801940), a randomized phase 3 trial evaluating apixaban and atorvastatin in patients with Covid19.Phase 3n = 2,631NCT04801940
• Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic: Complete Statistical AnalysisIndependent statistical analysis of Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 6,894NCT04385238
• Healthy, Immunized Communities Study: Complete Statistical AnalysisIndependent statistical analysis of Healthy, Immunized Communities Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03854734).Phase NAResults postedn = 148NCT03854734
• Heart Failure Polypill at a Safety Net Hospital: Complete Statistical AnalysisIndependent statistical analysis of Heart Failure Polypill at a Safety Net Hospital: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06029712).Phase 2Results postedn = 35NCT06029712
• Hepatitis B Booster Study in Adolescence: Complete Statistical AnalysisIndependent statistical analysis of Hepatitis B Booster Study in Adolescence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02169674).Phase 4Results postedn = 359NCT02169674
• Hepatitis C-Video vs. Brochure Education Delivery: Complete Statistical AnalysisIndependent statistical analysis of Hepatitis C-Video vs. Brochure Education Delivery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04204447).Phase NAResults postedn = 176NCT04204447
• HIBISCUSIndependent statistical analysis of Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 7NCT04860518
• Hidradenitis Suppurativa Phase 2b Study of Izokibep: Complete Statistical AnalysisIndependent statistical analysis of Hidradenitis Suppurativa Phase 2b Study of Izokibep: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05355805).Phase 2Results postedn = 205NCT05355805
• Hidradenitis Suppurativa Wound Care: Complete Statistical AnalysisIndependent statistical analysis of Hidradenitis Suppurativa Wound Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04354012).Phase 2Results postedn = 5NCT04354012
• High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population: Complete Statistical AnalysisIndependent statistical analysis of High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 4Results postedn = 112NCT05342532
• High MAP in Septic Shock With Hypertension: Complete Statistical AnalysisIndependent statistical analysis of High MAP in Septic Shock With Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01443494).Phase NAResults postedn = 19NCT01443494
• High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB): Complete Statistical AnalysisIndependent statistical analysis of High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 282NCT01936831
• High-dose vs. Standard-dose Cephalexin for Cellulitis: Complete Statistical AnalysisIndependent statistical analysis of High-dose vs. Standard-dose Cephalexin for Cellulitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04471246).Phase 4Results postedn = 69NCT04471246
• High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 20NCT01434472
• HIPCVAX-010SIndependent statistical analysis of Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 12NCT03701061
• HITCHIndependent statistical analysis of Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 96NCT04397718
• HIV and Kidney Function Study: Complete Statistical AnalysisIndependent statistical analysis of HIV and Kidney Function Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00905151).Phase NAResults postedn = 206NCT00905151
• HIV Self Testing of Male Partners of Women in PMTCT: Complete Statistical AnalysisIndependent statistical analysis of HIV Self Testing of Male Partners of Women in PMTCT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03484533).Phase NAResults postedn = 736NCT03484533
• HIV Vaccine Trial in Thai Adults: Complete Statistical AnalysisIndependent statistical analysis of HIV Vaccine Trial in Thai Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00223080).Phase 3Results postedn = 16,402NCT00223080
• Homeopathic Cold Medicine for Children: Complete Statistical AnalysisIndependent statistical analysis of Homeopathic Cold Medicine for Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00858494).Phase NAResults postedn = 50NCT00858494
• HORIZON 2Independent statistical analysis of A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 304NCT05007080
• HPTN 035Independent statistical analysis of HPTN 035, a randomized phase 2 factorial trial evaluating BufferGel and PRO 2000/5 vaginal gels for prevention of HIV infection in women.Phase 2n = 3,101NCT00074425
• Human Lung Responses to Respiratory Pathogens: Complete Statistical AnalysisIndependent statistical analysis of Human Lung Responses to Respiratory Pathogens: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01967628).Phase 1/2Results postedn = 98NCT01967628
• HVTN 120Independent statistical analysis of Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants: primary endpoint results, effect estimate with confidence interval,…Phase 1/2Results postedn = 160NCT03122223
• HVTN 503Independent statistical analysis of HVTN 503, a randomized phase 2 trial of a three-dose adenoviral HIV vaccine regimen in HIV-uninfected South African adults, including its endpoints, design, planned statistical methods, and interpretation.Phase 2n = 801NCT00413725
• HVTN 505Complete statistical analysis of HVTN 505, a randomized phase 2 trial of HIV-1 DNA plasmid and recombinant adenoviral vector vaccines in HIV-uninfected participants, including trial design, endpoints, Cox survival analyses, safety, and…Phase 2Results postedn = 2,504NCT00865566
• HVTN 702Independent statistical analysis of HVTN 702, a randomized phase 2/3 HIV vaccine prevention trial evaluating ALVAC-HIV and bivalent subtype C gp120/MF59 versus placebo, including time-to-event methods, hazard ratios, confidence intervals, safety, and…Phase 2/3Results postedn = 5,404NCT02968849
• Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection: Complete Statistical AnalysisIndependent statistical analysis of Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04372017).Phase 3Results postedn = 1NCT04372017

← All therapeutic areas